All In Biotech

NDA 208078 · Catalyst Pharms

Firdapse

Amifampridine Phosphate · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 28, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

15

8 Phase 3, 0 recruiting

FAERS reports

2,964

1,591 serious, 216 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 16, 2026.

FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. ( 1 )

Mechanism: The mechanism by which amifampridine exerts its therapeutic effect in LEMS patients has not been fully elucidated. Amifampridine is a broad-spectrum potassium channel blocker.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 30, 2024 Supplement 12 · Efficacy OrphanLetterLabel
  • Sep 29, 2022 Supplement 8 · Efficacy · priority review OrphanLetterLabel
  • Nov 28, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • FIRDAPSE · AMIFAMPRIDINE PHOSPHATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amifampridine" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthenia379
  • drug ineffective357
  • paraesthesia347
  • paraesthesia oral281
  • fall258
  • condition aggravated223
  • fatigue217
  • nausea210
  • muscular weakness204
  • headache191
  • diarrhoea177
  • dizziness175

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20176
20186
2019379
2020253
2021273
2022171
2023368
2024289
2025537
2026681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Firdapse (Amifampridine Phosphate)

2024 spending

$178M

Beneficiaries

402

3,824 claims

Per beneficiary

$442,345

$238.31 per unit

View as table
YearSpending
2020$79,392,496
2021$92,703,276
2022$126,614,542
2023$146,333,212
2024$177,822,831

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Catalyst Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.